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Background. A number of clinical systematic review and meta-analysis have been published on 
the use of tranexamic in the obstetric setting. The aim of this meta-analysis was to evaluate the safety 
and effectiveness of tranexamic acid in reducing blood loss when given prior to caesarean delivery.
Materials and methods. We searched the Cochrane Wounds Specialized Register, Cochrane 
Central, MEDLINE (through PUBMED), Embase, and SCOPUS electronic databases. We also searched 
clinical trials registries for ongoing and unpublished studies, and checked reference lists to identify 
additional studies. We used no restrictions with respect to language and date of publication. Two review 
authors independently performed study selection, "Risk of bias" assessment, and data extraction. Initial 
disagreements were resolved by discussion, or by including a third review author when necessary.
Results. We found 18 randomised controlled trials (RCTs) that met our inclusion criteria. Overall, 
1,764 women receiving intravenous tranexamic acid for prevention of bleeding following caesarean 
sections and 1,793 controls receiving placebo were enrolled in the 18 RCTs evaluated. The use of 
tranexamic acid compared to controls (placebo or no intervention) reduces post-partum haemorrhage 
>400 mL (risk ratio [RR] 0.40, 95% confidence interval [CI] 0.24-0.65; 5 trials with a total of 786 
participants), severe post-partum haemorrhage >1,000 mL (RR 0.32, 95% CI: 0.12-0.84; 5 trials with 
a total of 1,850 participants), and need for red blood cell transfusion (RR 0.30, 95% CI: 0.18-0.49; 10 
trials with a total of 1,873 participants). No particular safety concerns on the use of this antifibrinolytic 
agent emerged from the analysis of the 18 RCTs included.
Discussion. Overall, the results of this meta-analysis support the evidence of a beneficial effect of 
tranexamic acid in reducing blood loss and need for blood transfusion in pregnant women undergoing 
caesarean section. 
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Introduction
Obstetric haemorrhage is a leading cause of 
premature maternal mortality, accounting for at least 
100,000 deaths each year worldwide1-4. Although post-
partum haemorrhage (PPH) may be unpredictable, the 
most common causes include uterine atony, abnormal 
placentation, retained placental tissue, and lacerations 
of the lower genital tract5. In addition, obesity, multiple 
pregnancies, and previous caesarean section have been 
recognised as risk factors for PPH6. Considering the 
health and social burden of PPH, it is not surprising 
that a number of recommendations and guidelines have 
been issued from national and international scientific 
societies and health authorities to optimise the use of 
obstetric interventions and uterotonic drugs in this 
critical clinical setting7-9.
As far as the pathophysiology is concerned, recent 
evidence has linked the activation of the fibrinolytic 
pathway with the onset of severe haemorrhage in different 
settings, including trauma, heart and orthopaedic surgery, 
and obstetrics10,11. Following these observations, several 
randomised controlled trials (RCTs) have assessed 
the impact of tranexamic acid (TA), a lysine analogue 
that inhibits plasmin-mediated fibrin degradation12, on 
decreasing bleeding complications and mortality in such 
clinical conditions at increased haemorrhagic risk13-21. 
The aim of this paper is to provide an up-dated review, 
through a systematic analysis of the existing literature 
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on the published RCTs on the safety and efficacy of TA 
for prevention of postpartum blood loss. 
Material and methods
This systematic review was conducted according 
to the recommended Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) 
checklist guidelines22.
Search strategy 
A computer-assisted literature search of the 
MEDLINE (through PUBMED), EMBASE, SCOPUS, 
OVID and Cochrane Library electronic databases 
was performed to identify RCTs on the use of TA for 
prevention and treatment of PPH. A combination of 
the following text words was used to maximise search 
specificity and sensitivity: "tranexamic acid" AND 
"TXA" AND "antifibrinolytic agent" AND "post-
partum haemorrhage" AND "PPH" AND "obstetric 
haemorrhage" AND "caesarean" AND "vaginal" AND 
"randomized" AND "prevention" AND "treatment". 
In addition, we checked the reference lists of the most 
relevant items (original studies and reviews) in order 
to identify potentially eligible studies not captured by 
the initial literature search. Abstracts from relevant 
conferences or scientific meetings were hand-searched 
for additional studies.
Study selection and inclusion criteria
Study selection was performed independently by 
two reviewers (MF and MC), with disagreements 
resolved through discussion and on the basis of 
the opinion of a third reviewer (CM). Eligibility 
assessment was based on the title or abstract and on 
the full text if required. Articles were eligible if they 
reported either in the title or in the abstract the use of 
TA for the prevention of PPH. Only RCTs published 
in full in English between January 1970 and December 
2017 were included in this systematic review and meta-
analysis. As we found only two RCTs evaluating the 
efficacy of TA for the prevention of PPH after vaginal 
delivery23,24, the present analysis was limited to RCTs 
evaluating this antifibrinolytic agent after caesarean 
delivery. 
Data extraction and outcome analysis
For each study included in the systematic review, 
the following data were extracted by two reviewers 
(MF and MC) independently: publication date, sample 
size (TA and control groups), and protocol (TA dose 
administered). The primary outcome was the incidence 
of PPH (i.e. blood loss more than 400 mL) and severe 
PPH (i.e. blood loss >1,000 mL). Secondary outcomes 
included mean blood loss volume (mL), need for blood 
transfusion, and overall severe side effects related to 
TA (including thromboembolic events). Disagreement 
was resolved by consensus and by the opinion of a third 
reviewer, if necessary.
Assessment of risk of bias in included studies
Two review authors (MF and MC) independently 
assessed the risk of bias of each included study following 
the domain-based evaluation described in the Cochrane 
Handbook for Systematic Reviews of Interventions25. 
They discussed any discrepancies and achieved consensus 
on the final assessment. The Cochrane "Risk of  bias" 
tool addresses six specific domains: sequence generation, 
allocation concealment, blinding, incomplete data, 
selective outcome reporting, and other issues relating to 
bias. We have presented our assessment of risk of bias 
using two "Risk of bias" summary figures: 1) a summary 
of bias for each item across all studies; and 2) a cross 
tabulation of each trial by all of the "Risk of bias" items. 
"Summary of findings" tables
We used the principles of the GRADE system to 
assess the quality of the body of evidence associated 
with specific outcomes, and constructed a "Summary 
of findings" table using REVMAN 526. These tables 
present key information concerning the certainty 
of the evidence, the magnitude of the effects of the 
interventions examined, and the sum of available data for 
the main outcomes27. The "Summary of findings" tables 
also include an overall grading of the evidence related to 
each of the main outcomes using the GRADE approach, 
which defines the certainty of a body of evidence as the 
extent to which one can be confident that an estimate 
of effect or association is close to the true quantity of 
specific interest (see Online Supplementary Content, 
Table SI). The certainty of a body of evidence involves 
consideration of within-trial risk of bias (methodological 
quality), directness of evidence, heterogeneity, precision 
of effect estimates, and risk of publication bias28. 
We have presented the following outcomes in the 
"Summary of findings" table: i) PPH; ii) severe PPH; 
iii) need for blood transfusion (Table SI).
When evaluating the "Risk of bias" domain, we 
down-graded the GRADE assessment only when we 
classified a study as being at high risk of bias for one 
or more of the following domains: selection, attrition, 
reporting, and other bias; or when the "Risk of bias" 
assessment for selection bias was unclear (this was 
classified as unclear for either the generation of the 
randomisation sequence or the allocation concealment 
domain). For the outcomes PPH, need for blood 
transfusion, and post-partum blood loss, we did not 
down-grade for high risk of bias in performance and 
detection domains since we judged that the outcomes 
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4,567 citations identified through primary 
electronic and manual search 
4,502 citations excluded as not relevant according to the 
title and/or abstract 
 
65 potentially relevant records  
screened by 2 Reviewers 
(full-text articles assessed for eligibility) 
47 citations excluded (reviews, not RCTs, not enough 
information, involving other areas excluded) 
 
18 RCTs included in quantitative synthesis  
(meta-analysis) 
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Figure 1 -  Flow chart of study inclusion criteria. 
considered are not likely to be influenced by lack of 
blinding, and for unclear "Risk of bias" assessments in 
other domains. 
Data analysis 
All calculations were made using Stata 15.1, R 
v.3.4.3, and REVMAN 5. The effect size measures 
were the risk ratio (RR) and the risk difference (RD) 
between the treated arm and the control study arm. The 
study weight was calculated using the Mantel-Haenszel 
method. The heterogeneity χ2 was calculated as the I2 
for the variation due to heterogeneity25. If significant 
heterogeneity was detected, a random effect method of 
study weight calculation was followed (DerSimonian-
Laird method)29; otherwise, the fixed effect procedure 
was used. We also calculated the number needed to treat 
(NNT), which is the average number of patients who 
need to be treated in order to avoid (or to harm) an event. 
Results
Literature search and study characteristics 
In total, 4,567 articles were initially identified after 
the initial electronic and manual search, which was 
concluded on 7 January 2018 (Figure 1). Of them, 
4,502 were excluded because they were focusing on 
other topics. Thus, 65 potentially relevant articles were 
selected and the next screening led to the exclusion 
of 47 additional studies (reviews, protocols of RCTs, 
not RCTs, studies containing no informative data). 
The remaining 18 randomised studies30-47 were finally 
included in the systematic review and meta-analysis 
(see Table I for main characteristics and results of the 
included studies). Overall, 1,764 women receiving 
intravenous TA for prevention of bleeding following 
caesarean sections and 1,793 controls receiving placebo 
were enrolled in the 18 RCTs that went forward for 
evaluation. 
Risk of bias in included studies
Eleven studies were at high risk of bias for one or 
more domains, and 12 studies were at unclear risk of 
bias for one or more domains (Figure 2 A and B).
Allocation
We assessed two studies as being at high risk of 
selection bias, as randomisation was by alternation of 
the two treatments, so the intervention allocations could 
have been foreseen in advance31,40. The reports of six 
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Table I -  Characteristics and main results of the 18 randomised controlled trials on the use of tranexamic acid for the prevention 
of obstetric haemorrhage.
First  
Author, 
yearref.
Cases 
(IVTA/C)
Age, years1 IVTA dose Controls Post-partum 
blood loss, mL1 
PPH
onset
RBC 
transfusion
TA-related 
SAEs 
Gai,
200425
91/89 IVTA: 29.71 (4.18)
C: 29.75 (4.01)
1 g 10 min 
before CS
No 
treatment
IVTA: 359.29 (152.02)2
C: 439.36 (191.48)2
IVTA: 22/913
C: 35/893
NR IVTA: 0/91
C: 0/89
Sekhavat,
200926
45/45 IVTA: 26.2 (4.7)
C: 27.1 (4.1)
1 g 10 min 
before CS
5% glucose IVTA: 28.02 (5.53)4
C: 37.12 (8.97)4
NR NR IVTA: 0/45
C: 0/45
Gungorduk,
201127
330/330 IVTA: 26.3 (3.5)
C: 26.6 (3.6)
1 g 10 min 
before CS
5% glucose IVTA: 499.9 (206.4)5
C: 600.7 (215.7)5
IVTA: 7/3306
C: 19/3306
IVTA: 2/330
C: 7/330
IVTA: 0/330
C: 0/330
Movafegh,
201128
50/50 IVTA: 27.0 (3.4)
C: 27.6 (4.1)
10 mg/kg 20 
min before SA
Normal 
saline
IVTA: 262.5 (39.6)2
C: 404.7 (94.4)2
NR NR IVTA: 0/50
C: 0/50
Xu,
201329
88/86 IVTA: 26.7 (3.7)
C: 27.1 (4.1)
10 mg/kg 20 
min before SA
Normal 
saline
IVTA: 379.2 (160.1)2
C: 441.7 (189.5)2
IVTA: 19/887
C: 28/867
IVTA: 8/88
C: 19/86
IVTA: 2/88
C: 2/86
Shahid, 
201330
38/36 IVTA: 24.18 (3.93)
C: 24.89 (4.16)
1 g 10 min 
before CS
Normal 
saline
IVTA: 356.44 (143.2)2
C: 710.22 (216.72)2
NR IVTA: 3/38
C: 12/36
IVTA: 0/38
C: 0/36
Goswami,
201331
60/30 IVTA: 23.6 (2.5)
C: 24.3 (2.6)
10 or 15 mg/kg 
20 min before 
skin incision
5% glucose IVTA: 261.17 (56.78) 
–376.83 (31.96)8
C: 527.17 (88.67)8
IVTA: 0/606
C: 0/306
IVTA: 0/60
C: 2/30
IVTA: 0/60
C: 0/30
Senturk,
201332
101/122 IVTA: 30.2 (6.83)
C: 29.22 (6.93)
1 g 10 min 
before CS
5% glucose IVTA: 272.05 (143.23)
C: 346.87 (189.49)
NR IVTA: 0/101
C: 0/122
IVTA: 0/101
C: 0/122
Abdel-Aleem,
201333
373/367 IVTA: 26.34 (5.16)
C: 26.62 (5.05)
1 g 10 min 
before CS
No 
treatment
IVTA: 241.61 (126.02)2
C: 510.66 (144.52)2
IVTA: 2/3736
C: 2/3676
NR IVTA: 0/373
C: 0/367
Ghosh,
201434
70/70 IVTA: 25.94 (3.78)
C: 26.04 (3.39)
1 g 10 min 
before CS
Normal 
saline
IVTA: 48.06 (8.20)4
C: 76.01 (6.21)4
NR IVTA: 0/70
C: 3/70
IVTA: 0/70
C: 0/70
Singh,
201435
100/100 IVTA: 25 (1.46)
C: 30 (1.24)
1 g 20 min 
before CS
No 
treatment
IVTA: 270.05 (30.88)9
C: 510.45 (30.34)9
NR NR IVTA: 0/100
C: 0/100
Yehia,
201436
106/106 IVTA: 28.4 (4.9)
C: 28.6 (4.7)
1 g 20 min 
before CS
Normal 
saline
IVTA: 369.5 (198.0)9
C: 606.8 (193.0)9
IVTA: 33/1063
C: 67/1063
IVTA: 0/106
C: 2/106
IVTA: 0/106
C: 0/106
Gobbur,
201437
50/50 IVTA: 23.62 (3.43)
C: 24.5 (3.98)
1 g 20 min 
before CS
Normal 
saline
IVTA: 360.9 (110.3)2
C: 443.0 (88.55)2
IVTA: 6/507
C: 15/507
NR IVTA: 0/50
C: 0/50
Ramani,
201438
60/60 IVTA: 24.9 (3.9)
C: 24.4 (3.7)
1 g 10 min 
before CS
Normal 
saline
IVTA: 222.07 (97.02)2
C: 274.5 (179.2)2
NR IVTA: 2/60
C: 6/60
IVTA: 0/60
C: 0/60
Ahmed,
201539
62/62 IVTA: 28.6 (5.9)
C: 26.9 (5.2)
10 mg/kg 5 min 
before CS
Normal 
saline
IVTA: 391.0 (48.5)2
C: 596.7 (38.02)2
NR NR IVTA: 0/62
C: 0/62
Maged,
201540
100/100 IVTA: 24.9 (4.6)
C: 25.3 (4.7)
1 g 20 min 
before CS
Normal 
saline
IVTA: 459.4 (75.4)
C: 700.3 (143.9)
IVTA: 0/1006
C: 6/1006
NR IVTA: 0/100
C: 0/100
Lakshmi,
201641
60/60 IVTA: 26.77 (2.81)
C: 26.82 (2.8)
1 g 20 min 
before CS
No 
treatment
IVTA: 347.17 (108.6)9
C: 517.72 (150.0)9
IVTA: 2/607
C: 36/607
IVTA: 0/60
C: 0/60
IVTA: 0/60
C: 0/60
Sujata,
201642
30/30 IVTA: 29.4 (4.16)
C: 30.27 (4.31)
1 g 15 min 
before CS
Normal 
saline
IVTA: 432 (337-497)5,10
C: 819 (663-1001)5,10
IVTA: 0/306
C: 7/306
IVTA: 1/30
C: 4/30
IVTA: 0/30
C: 0/30
IVTA: intravenous tranexamic acid; C: controls; SD: standard deviation; min: minutes; CS: caesarean section; SAEs: severe adverse events; RBC: red blood 
cell transfusion; NR: not reported; PPH: post-partum haemorrhage; SA: spinal anaesthesia. 1Mean (standard deviation); 2measured from placental delivery to 
2 hours post-partum; 3defined as blood loss >400 mL; 4measured from the end of cesarean section to 2 hours post-partum; 5measured from the skin incision 
to 48 hours post-partum; 6defined as blood loss >1,000 mL; 7defined as blood loss >500 mL; 8measured from placental delivery to 24 hours post-partum; 
9measured from placental delivery to the end of caesarean section; 10median (interquartile range).
studies were unclear for random sequence generation 
and/or allocation concealment, while ten studies were 
at low risk of selection biases.
Blinding
There were nine studies reported as open label, 
and they were graded as high risk of performance bias 
(blinding of participants and personnel). Eight studies 
were reported as double blind32-37,39,41,47, and one45 as 
single blind; one of these studies37 did not provide 
any information on the blinding procedures. Eleven 
studies were graded at unclear risk of detection bias 
due to the fact that it did not provide information to 
permit judgement about "high" or "low" risk of bias 
related to the blinding of outcome assessors; one study44 
was graded at high risk of bias because it stated that 
the clinical care team was aware of the administered 
treatment.
Incomplete outcome data
One study45 was judged at high risk of attrition bias 
because it reported only per protocol analysis. Two 
studies31,44 were judged at unclear risk of bias. The 
remaining studies were judged at low risk of bias.
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Figure 2 - Risk of bias graph and summary. 
 (A) Review authors' judgements about each risk of 
bias item presented as percentages across all included 
studies. (B) Review authors' judgements about each 
risk of bias item for each included study.
Selective reporting
Selective reporting was low in all included studies, 
and graded as "unclear" in one study35 where some data 
were not presented in detail (e.g. some side effects) 
although the report states that there were no differences 
between groups.
Other potential sources of bias
We judged three studies at high risk of other source 
of bias: two because of imbalance at baseline37,38, and 
one36 because it did not mention PPH, enrolled anaemic 
women, and because there was a significant difference 
in the duration of surgery between groups.
Effects of interventions
The overall incidence of PPH was 71 cases on 395 
treated patients (17.9%) and 172 cases on 391 control 
patients (43.9%). Using the average treatment effect 
from a random-effects model, the use of TA reduces 
significantly the episodes of PPH when compared with 
control group: five trials, 786 patients; RR 0.40, 95% CI: 
0.24-0.65; p=0.0003 for overall effect; I²=68% (Figure 
3A). The overall incidence of severe PPH was 9 cases of 
893 treated patients (1.0%) and 34 cases of 857 control 
patients (3.9%). Using the average treatment effect from 
a random-effects model, the use of TA significantly 
reduces the episodes of severe PPH when compared 
with control group: five trials, 1, 750 patients; RR 0.32, 
95% CI: 0.12-0.84; p=0.02 for overall effect; I²=19% 
(Figure 3B).
As far as secondary outcomes are concerned, 
using the average treatment effect from a fixed-effects 
model, the use of TA reduces the need of red blood 
cell transfusion compared to controls: ten trials, 1,873 
patients; RR 0.30, 95% CI: 0.18-0.49; p=0.00001 for 
overall effect; I²=0% (Figure 4). The overall incidence 
for blood transfusion was 16 cases of 943 treated patients 
(1.69%) and 55 cases of 930 control patients (5.91%). 
The NNT was calculated as 25.6.
Tranexamic acid reduces the amount (mL) of 
post-partum blood loss: mean difference −155.14 
(95% CI: −192.69 to −157.58; p=0.00001 for overall 
effect) (Figure 5). The direction of the effect was 
consistent across studies, with a beneficial effect 
of TA, but there was a considerable heterogeneity 
(I²=100%). The heterogeneity observed can be ascribed 
to different intervals of blood loss recorded (from 
placental delivery30,33-35,38,42-44 or caesarean section39 to 
two hours post-partum, from skin incision to 48 hours 
post-partum32,47, from placental delivery to 24 hours 
post-partum36, from placental delivery to the end of 
caesarean section40,41,46); to different populations of 
patients enrolled (e.g. several studies excluded anaemic 
women, but one study36 included only anaemic women); 
(A)
(B) 
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Figure 4 - Forest plot of the effect of tranexamic acid (TA) on red blood cell (RBC) transfusion need. 
M-H: Mantel-Haenszel; CI: confidence interval.
Figure 3 - Forest plot demonstrating effects of tranexamic acid (TA) on the incidence of (A) post-
partum haemorrhage and (B) severe post-partum haemorrhage. 
 M-H: Mantel-Haenszel; CI: confidence interval.
Figure 5 -  Forest plot of tranexamic acid (TA) on post-partum blood loss (mL). 
 CI: confidence interval. 
(A)
(B) 
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to different dosage of TA used; and also to methods used 
to quantify the loss (e.g. weight of gauze pads, and/or 
sponges, mops, drapes; bloods in suction bottles; pre- 
and post-intervention haemoglobin values).
One study34 reported severe side effects (deep vein 
thrombosis) in 2 of 88 TA recipients and in 2 of 86 
controls (RR, 0.98, 95% CI: 0.14-6.78). The remaining 
17 studies did not report severe adverse events, including 
thromboembolic events, in either group.
Based on GRADE assessment, all these comparisons 
were graded as moderate certainty evidence, and down-
graded once due to inconsistency or to risk of biases (see 
Online Supplementary Content, Table SI).
Discussion
The antifibrinolytic agent TA is routinely used 
in cardiac, orthopaedic and oral surgeries to reduce 
perioperative blood loss13-15. Recent evidence 
from RCTs also indicate that TA usage results in a 
significant reduction of obstetric bleeding20,48,49. A 
recent randomised, placebo-controlled trial (WOMAN, 
WOrld Maternal ANtifibrinolytic) on 20,060 women 
with PPH found that TA reduces deaths due to bleeding 
(RR 0.81, 95% CI: 0.65-1.00; p=0.045) with no adverse 
effects, especially when given early after bleeding 
onset50. A Cochrane systematic review evaluating 
TA for preventing post-partum haemorrhage was 
recently published. After the analysis of 12 RCTs 
involving 3,285 women, the authors concluded that TA 
decreases postpartum blood loss and prevents PPH and 
blood transfusion requirements51. The results of our 
meta-analysis are in line with these observations and 
indicate that, in women undergoing caesarean delivery, 
the prophylactic use of TA significantly reduces the 
incidence of PPH, including severe PPH, total blood 
loss and transfusion requirements without increasing 
the risk of thromboembolic complications. The main 
strength of our study is that it represents a very large, 
up-to-date and comprehensive analysis which involved 
overall 4,557 women enrolled in 18 RCTs. In addition, 
most of the included studies are of high quality and 
with a low risk of bias according to the Cochrane risk 
of bias tools. Nevertheless, our systematic review has 
some limitations which are related to the different study 
designs of the RCTs evaluated that generate a substantial 
heterogeneity across studies. For instance, there were 
differences among the various RCTs in the definition 
of PPH (blood loss >400 or >500 mL) and post-partum 
blood loss assessment (2 hours, 24 hours or 48 hours 
post-partum). In particular, the abbreviated time for 
data collection may mean that total blood loss and the 
true incidence of PPH have been under-estimated. In 
addition, we were not able to detect the effect of TA 
on maternal death due to the lack of fatal events in the 
studies evaluated, which was probably related to the 
small size of the population of women enrolled. Larger 
RCTs on this clinical setting are, therefore, needed to 
assess this important outcome. 
In summary, the results of our meta-analysis 
document the safety and efficacy of prophylactic 
administration of TA in reducing post-partum blood 
loss, PPH incidence and need for blood transfusion in 
women undergoing caesarean delivery. Therefore, given 
its efficacy in preventing one of the most common and 
serious complications of pregnancy, we recommend 
the use of TA in this clinical setting. The use of this 
drug in the framework of patient blood management 
(PBM) programmes52-55 can play a key role as a 
strategy to save blood loss but, to be really beneficial 
in improving patient outcome and efficient for health 
systems, it should be part of an adequate management of 
perioperative anaemia56, 57. In fact, the benefits of a PBM 
programme58 are greater when it includes optimisation 
of patient's haemoglobin level59-65. This approach is very 
important also for the perinatal care of women, a setting 
where the management of anaemia and haematinic 
deficiencies should be obligatory both for clinicians and 
policymakers in charge of decision making processes 
aimed at up-dating clinical practice in health care66. 
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